Related references
Note: Only part of the references are listed.Persistent N2 After Induction Is Not a Contraindication to Surgery for Lung Cancer
Weston G. Andrews et al.
ANNALS OF THORACIC SURGERY (2022)
Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline
Megan E. Daly et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Gefitinib as neoadinvant therapy for resectahle stage II-IIIA non-small cell lung cancer: A phase II study
Yang Zhang et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2021)
Outcomes of salvage lung resections in advanced EGFR-mutant lung adenocarcinomas under EGFR TKIs
Ying-Yuan Chen et al.
THORACIC CANCER (2021)
A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy
Ranpu Wu et al.
FRONTIERS IN ONCOLOGY (2021)
Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
Liwen Xiong et al.
ONCOLOGIST (2019)
Outcomes of surgery versus chemoradiotherapy in patients with clinical or pathologic stage N3 non-small cell lung cancer
Vignesh Raman et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2019)
The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis
Hengrui Liang et al.
JOURNAL OF THORACIC DISEASE (2018)
Surgery for advanced non-small cell lung cancer patient after epidermal growth factor receptor tyrosine kinase inhibitor neoadjuvant therapy
Ye Ning et al.
ANNALS OF TRANSLATIONAL MEDICINE (2018)
EGFR Mutation Subtypes Influence Survival Outcomes' following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients
Natalia Sutiman et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Stage III Non-small Cell Lung Cancer
Valerie W. Rusch
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2016)
Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
Feng-Che Kuan et al.
BRITISH JOURNAL OF CANCER (2015)
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial)
F. Kocher et al.
LUNG CANCER (2014)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer:: 5-year follow-up of a phase II study
DC Betticher et al.
BRITISH JOURNAL OF CANCER (2006)
Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial
DC Betticher et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
